Hong Kong Stock Movement: PEGBIO CO-B fell 10.12%, with clear capital flow, volatility attracting market attention

Hong Kong Stock Movement PEGBIO CO-B fell 10.12%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranked by Industry Transaction Volume Kejia Pharmaceutical-B fell 8.76%. Based on recent key news: On May 15, Kejia Pharmaceutical announced a rights issue at a discount of 9.49%, raising approximately HKD 462 million. This move led to a drop in stock price, which fell 6.48% at the opening, with a transaction volume reaching HKD 622 million. Source: Zhitong Finance On May 15, shareholders of Kejia Pharmaceutical deposited shares into UBS Securities Hong Kong, with a market value of HKD 1.927 billion, accounting for 14.5%. This move may affect market confidence in the stock. Source: Zhitong Finance On May 15, the proceeds from the rights issue of Kejia Pharmaceutical will be used for the research and development of innovative drugs and capital expenditures for production facilities, with approximately 70% allocated for global clinical development. This aims to accelerate pipeline development and expand indications. Source: Zhitong Finance. The capital flow indicates active trading, and risks need to be monitored. Innovent Biologics fell 5.88%. Based on recent key news: On May 12, JP Morgan released a report stating that the adjustment plan for the drug catalog announced by the National Healthcare Security Administration will accelerate the commercialization process of innovative drugs. Innovent Biologics, as an innovative drug company, will benefit from the shortened application time for the healthcare catalog and the connection mechanism between commercial insurance and the national healthcare catalog. This policy change is seen as a catalyst for the stock price volatility of Innovent Biologics. Source: JP Morgan On May 12, JP Morgan reiterated its positive view on Innovent Biologics and listed it as an industry preferred stock. Nevertheless, market concerns about the short-term effectiveness of policy implementation may lead to a decline in stock price. Source: JP Morgan On May 12, the optimistic sentiment in the overall outlook for the innovative drug industry failed to offset the short-term stock price volatility of Innovent Biologics. Investors may be waiting for clearer details on policy implementation. Source: JP Morgan. The policy changes in the innovative drug industry have significant impacts. Kangfang Biologics fell 2.50%, with a transaction volume reaching HKD 191 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranked by Industry Market Capitalization BeiGene fell 2.65%. Based on recent key news: On May 14, BeiGene announced that its drug Brukinsa received accelerated approval from the U.S. FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. This approval provides significant support for the company's expansion in the U.S. market, driving stock price volatility. On May 11, BeiGene released its first-quarter earnings report, with revenue rising 31% to HKD 10.544 billion, and a net profit of HKD 1.608 billion, turning profitable compared to the same period last year. The improvement in performance has enhanced market confidence in the company's future growth Since May, BeiGene has received attention from a total of 146 institutions, indicating the market's high regard for its innovative drug pipeline, which further influences stock price trends. The pharmaceutical sector is experiencing high prosperity, with significant capital inflows